Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

The approved indications for Yescarta are adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal ... with B-cell acute lymphoblastic leukaemia ...

A new study finds that statin use significantly improves survival outcomes in patients with chronic lymphocytic leukemia or ...

and small lymphocytic lymphoma (SLL). Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented ...

In this small study, huCART19-IL18 had a safety profile consistent with other CAR T-cell treatments and showed promising efficacy at low cell doses in patients with lymphoma after the failure of ...

16-year-old Ayla Marecek was diagnosed with Lymphoblastic Lymphoma last fall, and the community wanted to do something to help her and her family. A group of women from Clinton County started a ...

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

Callum Lane was diagnosed with T-cell lymphoblastic lymphoma, a fast-growing and aggressive form of cancer, in February 2023 after noticing 'unusual lumps' on his neck. Callum was quickly referred ...

FOX CHASE (WPVI) -- We often connect cancer to one part of the body. Lymphoma, however, can attack almost anywhere. But a treatment pioneered here in Philadelphia is rapidly improving the odds for ...

Calquence is approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the US, Japan and China, and approved for CLL in the EU and many other countries.